Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant

References

• AndrewsPINaylorRJJossRANeuropharmacology of vomiting and its relevance to anti-emetic therapy. Consensus and controversiesSupport Care Cancer199861972039629870
   PubMed Web of Science ®Google Scholar
• BergmanAJMarburyTFosbinderTEffect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitantClin Pharmacokinet2005446374715910011
   PubMed Web of Science ®Google Scholar
• BlumRAMajumdarAMcCreaJEffects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjectsClin Ther20032514071912867217
   PubMed Web of Science ®Google Scholar
• Boer-DennertMWitRSchmitzPJPatient perceptions of the side effects of chemotherapy: the influence of the 5-HT3 antagonistsBr J Cancer1997761055619376266
   PubMed Web of Science ®Google Scholar
• CamposDPereiraJRReinhardtRRPrevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone aloneJ Clin Oncol20011917596711251007
   PubMed Web of Science ®Google Scholar
• ChawalaSPGrunbergSMGrallaRJEstablishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomitingCancer200397229030012712486
   PubMed Web of Science ®Google Scholar
• CocquytVVan BelleSReinhardtRRComparison of L-758,298 a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin induced emesisEur J Cancer2001378354211313170
   PubMed Web of Science ®Google Scholar
• De JongeMEHuitemaADHoltkampMJAprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolismCancer Chemother Pharmacol200556370815838656
   PubMed Web of Science ®Google Scholar
• DepreMVan HeckenAOeyenMEffect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarinEur J Clin Pharmacol200561341615983826
   PubMed Web of Science ®Google Scholar
• De WitRHerrstedtJRapoportBAddition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapyJ Clin Oncol20032141051914559891
   PubMed Web of Science ®Google Scholar
• GrallaRJOsobaDKrisMGRecommendations for the use of antiemetics: evidence-based, clinical practice guidelinesJ Clin Oncol19991729719410561376
   PubMed Web of Science ®Google Scholar
• GroteTHajdenbergJCartmellACombination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitantJ Support Oncol20064403817004515
   PubMedGoogle Scholar
• GrunbergSMDeusonRRMavrosPIncidence of chemotherapy-induced nausea and emesis after modern antiemeticsCancer20041002261815139073
   PubMed Web of Science ®Google Scholar
• HaleJJMillsSGMacCossMPhosphorated morpholine acetal human neurokinin-1 receptor antagonists as water soluble prodrugsJ Med Chem20004312344110737756
   PubMed Web of Science ®Google Scholar
• HargreavesRImaging substance P receptors (NK1) in the living human brain using positrom emission tomographyJ Clin Psychiatry200263182412562139
   PubMed Web of Science ®Google Scholar
• HerrstedtJMussHBWarrDGEfficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapyCancer200510415485516104039
   PubMed Web of Science ®Google Scholar
• HeskethPADefining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practiceOncologist19994191610394587
   PubMedGoogle Scholar
• HeskethPJGrunbergSMGrallaRJThe oral neurokinin-1 antagonists aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The aprepitant protocol 052 study groupJ Clin Oncol2003214112914559886
   PubMed Web of Science ®Google Scholar
• HeskethPJGrunbergSMHerrstedtJCombined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment responseSupport Care Cancer2006143546016450086
   PubMed Web of Science ®Google Scholar
• KrisMGGrallaRJClarkRAIncidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatinJ Clin Oncol198531379844045527
   PubMed Web of Science ®Google Scholar
• KrisMGCubedduLXGrallaRJAre more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatinCancer199678219388918414
   PubMed Web of Science ®Google Scholar
• LasseterKCGambaleJJinBTolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjectsJ Clin Pharmacol2007478344017525168
   PubMed Web of Science ®Google Scholar
• LoosWJde WitRFreedmanSJAprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patientsCancer Chemother Pharmacol2007594071217051369
   PubMed Web of Science ®Google Scholar
• McCreaJBMajumdarAKGoldbergMREffects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisoloneClin Pharm Ther2003741724
   PubMed Web of Science ®Google Scholar
• MaJGMartinARCaridesADThe oral NK1 antagonist, aprepitant, is effective in reducing impact of chemotherapy-induced nausea and vomiting on daily life in both younger and older patients receiving highly emetogenic chemotherapyProc Am Soc Clin Oncol200322785
   Google Scholar
• MartinARCaridesADPearsonJDFunctional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitantEur J Cancer200339139540112826042
   PubMed Web of Science ®Google Scholar
• Merck and Co IncProduct Information. Emend IV™ (fosaprepitant dimeglumine, MSD) Approved by TGA Therapeutics Goods Administration 14 Aug 20072007
   Google Scholar
• MooreSTumehJWojtanowskiSCost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapyValue Health200710233117261113
   PubMed Web of Science ®Google Scholar
• MorrowGRPrevalence and correlates of anticipatory nausea and vomiting in chemotherapy patientsJ Natl Cancer Instit19826858593
   PubMed Web of Science ®Google Scholar
• NavariRMReinhardtRRGrallaRJReduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonistN Engl J Med199934019059917226
   PubMed Web of Science ®Google Scholar
• NavariRMFosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingExpert Opin Investig Drugs200716197785
   PubMed Web of Science ®Google Scholar
• NygrenPHandeKPettyKJLack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patientsCancer Chemother Pharmacol2005556091615723220
   PubMed Web of Science ®Google Scholar
• OechsleKMullerMRHartmannJTAprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT (3) antagonists and dexamethasoneOnkologie2006295576117202825
   PubMed Web of Science ®Google Scholar
• OlverIPaskaWDepierreAA multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesisAnn Oncol19967945529006746
   PubMed Web of Science ®Google Scholar
• OlverIShelukarSThompsonKNanomedicines in the treatment of emesis during chemotherapy: focus on aprepitantInt J Nanomedicine20072131817722507
   PubMed Web of Science ®Google Scholar
• OsobaDZeeBWarrDEffect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of life and symptom control committees of the National Cancer Institute of Canada Clinical Trials GroupSupport Care Cancer19975307139257427
   PubMed Web of Science ®Google Scholar
• Poli-BigelliSRodrigues-PereiraJCaridesADAddition of the neurokinin 1 antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin AmericaCancer2003973090812784346
   PubMed Web of Science ®Google Scholar
• SchmollHJAaproMSPoli-BigelliComparison of aprepitant regimes with a multiple day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatmentAnn Oncol2006171000616524979
   PubMed Web of Science ®Google Scholar
• ShahAKHuntTLGallagherSCPharmacokinetics of palonosetron in combinations with aprepitant in healthy volunteersCurr Med Res Opin20052159560115899109
   PubMed Web of Science ®Google Scholar
• SmithARRepkaTLWeigelBJAprepitant for the control of chemotherapy induced nausea and vomiting in adolescentsPediatr Blood Cancer2005458576015849684
   PubMed Web of Science ®Google Scholar
• TattersallFDRycroftWCumberbatchMThe novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferretsNeuropharmacology2000396526310728886
   PubMed Web of Science ®Google Scholar
• Van BelleSLichinisterMRNavariRMPrevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: a randomized controlled trialCancer20029430324112115394
   PubMed Web of Science ®Google Scholar
• WarrDGHeskethPJGrallaRJEfficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emtogenic chemotherapyJ Clin Oncol20052328823015728220
   PubMed Web of Science ®Google Scholar
• WatsonJWGonsalvesSFRossaAAThe antiemetic effects of CP-99,994 in the ferret and dog: role of the NK-1 receptorBr J Pharmacol199811584947544198
   PubMed Web of Science ®Google Scholar